GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Glatter is an assistant professor of emergency medicine.

Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 ...

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard of them under brand names like Ozempi c® and Wegovy ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...